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 Chronic kidney disease (CKD) is charac-
terized by a progressive loss of renal func-
tion that oft en leads to end-stage kidney 
disease and high mortality. Th ere is exten-
sive evidence that the renin – angiotensin 
system (RAS) is a major mediator of pro-
gressive renal injury in CKD. Drugs that 
target the RAS, including angiotensin-
converting enzyme inhibitors (ACEIs) 
and angiotensin II type 1 receptor block-
ers (ARBs), have been shown to slow the 
progression of glomerulosclerosis, tubu-
lointerstitial fi brosis, and proteinuria. 1,2 
Intrarenal angiotensin II (Ang II) and 
angiotensin-converting enzyme activity 
exert multiple eff ects on the kidney that 
promote progression of renal injury. 
These effects include an increase in 
glomerular capillary pressure, induction 
of profibrotic and proinflammatory 
cytokines, promotion of infl ammatory-
cell infi ltration, stimulation of cell prolif-
eration and hypertrophy, and upregulation 
of extracellular matrix (ECM) synthesis. 
The hormonal form of vitamin D, 
1,25 – dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), 
is a negative endocrine regulator of the 
RAS. 3,4 1,25(OH) 2 D 3 suppresses renin 
biosynthesis, and homozygous mutant 
mice lacking the vitamin D receptor 
(VDR) gene develop high renin hyper-
tension, cardiac hypertrophy, and 
increased thrombogenicity. Recent stud-
ies have shown that VDR-defi cient dia-
betic mice develop a more severe 
nephropathy than wild-type mice, 5,6 
suggesting that vitamin D plays a protec-
tive role against hyperglycemia-induced 
renal injury. Th ese observations provide 
the rationale for studies exploring 
whether co-treatment with low-calcemic 
vitamin D analogs and ACEIs / ARBs has 
additive or synergistic therapeutic eff ects 
on the progression of proteinuric 
kidney disease. 
 RAS inhibitors, including ACEIs and 
ARBs, are widely used in the therapy of 
renal and cardiovascular diseases. Th e 
major limitation of these drugs is the 
compensatory rise in renin levels due to 
the disruption of the feedback inhibition 
of renin production. 7,8 High renin 
buildup increases the risk of Ang II-
dependent and -independent organ dam-
age, which may limit the effi  cacy of RAS 
inhibition and may be the cause of the 
resistance to therapy sometimes seen 
with the use of ACEIs and / or ARBs. 
Because low-calcemic vitamin D analogs 
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 Vitamin  D  analogs may slow the progression of chronic kidney disease. 
Tan  et al. report that paricalcitol has additive effects with an 
angiotensin-converting enzyme inhibitor (ACEI) in suppressing 
extracellular matrix expression, interstitial inflammation, and 
myofibroblast activation in obstructive nephropathy. Paricalcitol 
inhibited renin transcription, countering the compensatory ACEI-
induced rise in renin, thus achieving a more complete blockade of the 
renin – angiotensin system (RAS). Vitamin D analogs may enhance the 
renoprotective effects of RAS inhibitors. 
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are able to inhibit renin expression in 
animals, 9 Tan  et al. 10 (this issue) rea-
soned that combining a vitamin D analog 
with a RAS inhibitor to suppress the 
reactive renin increase should generate 
additive therapeutic eff ects and amelio-
rate renal interstitial fi brosis and infl am-
mation. To test this concept, they 
administered a combination of trandol-
april, an ACEI, and paricalcitol (19 – nor-
1,25 – dihydroxyvitamin D 2 ) to mice with 
unilateral ureteral obstruction (UUO). 
Paricalcitol   is an activated vitamin D 
analog that stimulates the VDR at low 
concentrations and suppresses renin 
expression in mice with the same potency 
as calcitriol but without inducing hyper-
calcemia. Th e combination resulted in 
reductions in the expression of proteins 
or mRNAs for ECM components, tubular 
epithelial-to-mesenchymal transition 
markers, and proinfl ammatory cytokines, 
as well as a reduction in the invasion by 
CD3   +   T cells and macrophages ( Figure 1 ). 
Th e authors ’ data suggest that   the com-
bination of an ACEI and a vitamin D 
analog markedly reduces renal injury, 
presumably because of the more 
complete inhibition of the RAS within 
the kidney. 
 Th e expression of the VDR in virtually 
all tissues in the body, including the kid-
ney, is the basis for postulating broad non-
calcemic actions for vitamin D beyond the 
regulation of calcium and phosphorus 
homoeostasis. Recent studies using a vari-
ety of experimental models, including 
UUO, have shown that vitamin D analogs 
may be renoprotective by reducing pro-
teinuria, renal infl ammation, and fi bro-
sis. 11 – 13 Th e most prominent feature of 
fi brosis is the increased accumulation of 
ECM in the interstitial space. Th e UUO 
model is a well-established, although 
aggressive, model of acute tubulointersti-
tial fibrosis with high inflammatory 
response. In the obstructed kidney, pari-
calcitol suppressed the induction of ECM 
proteins, including fi bronectin and type I 
and type III collagens, as well as   -smooth 
muscle actin, a marker for EMT. 10 Not 
surprisingly, the profi brotic transforming 
growth factor-   pathway was also 
repressed by paricalcitol. In stark contrast, 
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vitamin D analogs dramatically increases 
the therapeutic effi  cacy of the conven-
tional RAS inhibitors in the UUO model. 
Whether vitamin D analogs have addi-
tional advantages over the selective renin 
inhibitor aliskiren is not addressed in this 
study. However, aliskiren, while it reduces 
renin activity, may increase plasma renin 
concentrations, which may be a major 
limitation of this drug. 15 In contrast, the 
inhibitory eff ect of vitamin D analogs on 
renin transcription and biosynthesis may 
be a signifi cant advantage. 
 Furthermore, vitamin D analogs may 
also have signifi cant anti-infl ammatory 
properties that may make them uniquely 
advantageous over more selective renin 
inhibitors. A major anti-infl ammatory 
eff ect of paricalcitol seems to be due to its 
stabilizing eff ect on NF-  B. Th e NF-  B 
nuclear transcription pathway is a master 
regulator of immune responses and is piv-
otal in the regulation of inflammatory 
cytokines and fi brogenic molecules that 
are involved in the development of kidney 
disease. Numerous studies have demon-
strated the suppression of NF-  B activa-
tion by vitamin D analogs, partly through 
blockade of nuclear translocation of NF-
  B DNA. Paricalcitol, the vitamin D ana-
log used by Tan  et al. , 10 was   previously 
shown by the same authors to reduce renal 
infl ammation by blocking NF-  B activity 
in UUO mice. 13 Although paricalcitol or 
trandolapril alone can directly suppress 
the induction of regulated on activation 
normal T cell expressed and secreted 
(RANTES) and tumor necrosis factor-  
expression aft er obstructive injury, the 
current study by Tan and colleagues 10 
showed that co-treatment with paricalci-
tol and trandolapril achieved a better inhi-
bition of these cytokines and renal 
infi ltration of infl ammatory T cells and 
macrophages  in vivo . Because RANTES 
and tumor necrosis factor-  are upregu-
lated by Ang II, the suppression of these 
factors by co-treatment is likely mediated 
by the blockade of both Ang II accumula-
tion and NF-  B activation ( Figure 1 ). 
 The molecular basis underlying the 
impressive antiproteinuric and antiscle-
rotic eff ects of the combination therapy is 
the blockade of RAS activation within the 
kidney and simultaneous achievement of 
anti-infl ammatory eff ects. Th e eff ect of 
VDR-null genetic mutant mice developed 
a more severe interstitial fi brosis with the 
UUO model. Th e present report by Tan  et 
al. 10 clearly shows an additive or synergis-
tic eff ect of paricalcitol and trandolapril 
co-treatment on renal fi brosis and infl am-
mation in the mouse UUO model. 
 Th e local intrarenal RAS is an impor-
tant determinant of kidney tissue injury, 
contributing to infl ammation and the pro-
gression of renal disease. Inhibition of the 
actions of the RAS can preserve renal 
function in CKD. The non-calcemic 
actions of vitamin D analogs that may 
help protect the kidney include regulation 
of the local RAS and the nuclear factor-  B 
(NF-  B) pathway, which promote renal 
damage and the progression of kidney 
disease characterized by proteinuria, 
glomerulosclerosis, and tubulointerstitial 
fi brosis. 14 Kidney cells have the capacity 
to synthesize all components of the RAS, 
which are highly inducible by an initial 
insult. In CKD, the intrarenal interstitial 
Ang II levels can reach as much as 1000 
times higher than those in plasma. Cur-
rently, ACEIs, ARBs, and the renin inhib-
itor aliskiren remain fi rst-line treatments 
for the progression of CKD; however, not 
all patients respond to these treatments, 
in many cases because of incomplete 
blockade of the RAS. Tan  et al. 10 have now 
demonstrated that blocking the compen-
satory increase of renin expression with 
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 Figure 1  |  Renoprotective effects of combination therapy with renin – angiotensin 
system inhibitors and vitamin D receptor activators in chronic kidney disease. Various 
injuries to the kidney stimulate the intrarenal renin – angiotensin system (RAS) and lead to 
proinflammatory / inflammatory cytokine production, infiltration of inflammatory T cells and 
macrophages, and induction of epithelial-to-mesenchymal transition (EMT). The activation of 
the RAS results in suppression of renin gene expression. When the system is inhibited with an 
angiotensin-converting enzyme inhibitor (ACEI), angiotensin II type 1 receptor blocker (ARB), 
or renin enzymatic inhibitor, this feedback loop is disrupted, leading to overexpression of renin. 
The compensatory renin overproduction will increase angiotensin II (Ang II) conversion, thus 
decreasing the efficacy of inhibition of the RAS. Activation of the RAS and the transcription factor 
nuclear factor-  B (NF-  B) results in increased production of cytokines, including transforming 
growth factor-  1 (TGF-  1), which plays pivotal roles in causing renal damage. Vitamin  D  and 
its analogs bind to the vitamin D receptor (VDR) and transcriptionally inhibit renin expression, 
counterbalance extracellular matrix (ECM) synthesis by inhibiting TGF-  1, and suppress 
NF-  B activation. An active vitamin D analog combined with a RAS inhibitor (ACEI, ARB, or renin 
inhibitor) will block the compensatory expression of renin and, therefore, synergistically achieve 
a more complete RAS inhibition. AT1R, angiotensin II type 1 receptor; IL, interleukin; MCP-1, 
monocyte chemoattractant protein-1; RANTES, regulated on activation normal T cell expressed 
and secreted; TNF  -  , tumor necrosis factor-  . 
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paricalcitol was seen even in subjects 
already treated with ACEIs or ARBs, indi-
cating that the vitamin D analog has addi-
tive or synergistic eff ects with ACEIs / ARBs 
in reducing proteinuria. In a randomized 
double-blind pilot trial, Alborzi  et al. 16 
reported that paricalcitol treatment for 1 
month signifi cantly reduced albuminuria 
and inflammatory status in the drug-
treated subjects, and these eff ects were 
independent of its eff ects on hemodynam-
ics and parathyroid hormone suppression. 
Th e anti-albuminuric eff ect of vitamin D 
analogs is of particular signifi cance, as 
albuminuria is a major risk factor for the 
progressive decline of renal function and 
is believed to harbinger an inevitable pro-
gression to overt proteinuria and renal 
failure. Th us, reduction of albuminuria is 
a convincing and favorable eff ect during 
renoprotective therapy. 
 Trandolapril treatment markedly 
increased renin levels in the kidney. Yet 
combination treatment with trandolapril 
and paricalcitol markedly attenuated the 
induction of renin and Ang II. Th us, in 
the combination therapy, paricalcitol 
blocked the increase in renin, minimizing 
the Ang II-independent activation of the 
prorenin / renin receptor, which may also 
contribute to renal damage. Together 
these actions of the combination therapy 
lead to an eff ective strategy to counter the 
development of CKD. 
 Th e renoprotective eff ect of paricalcitol, 
however, appears to be not limited to the 
regulation of the RAS. Th e anti-infl amma-
tory properties of vitamin D and its 
analogs may further enhance their 
renoprotective eff ects in kidney disease. 
Th is study off ers new insights into a novel 
therapeutic approach for further clinical 
studies. Given the limitations of animal 
models, whether this therapeutic strategy 
also works in humans requires further 
clinical investigations. 
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 Gene  identification via positional 
cloning represents a form of deliberate 
ascertainment bias. Of necessity, 
researchers study families with extreme 
forms of disease to maximize the ability 
of these studies to succeed. In studies of 
dominantly inherited phenotypes, for 
example, it is typically through the study 
of large, multigenerational pedigrees 
with high penetrance that geneticists can 
home in on a narrowly defi ned genetic 
locus, and ultimately a single mutant 
gene. Although recessive families typi-
cally do not present as multigenerational, 
extended pedigrees (except in the pres-
ence of signifi cant inbreeding), it is sim-
ilarly typical for the initial success in a 
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 Expanding the spectrum 
of  NPHS1 -associated disease 
 Martin R.  Pollak 1 
 The nephrin gene  NPHS1  was cloned in 1998. Studies in families with 
congenital nephrotic syndrome led to the identification of this critical 
component of the glomerular slit diaphragm. Studies such as the new 
one by Sant í n  et al. are expanding our understanding of the spectrum of 
disease associated with  NPHS1 mutations. 
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